Cargando…
Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
Autores principales: | Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., Baird, R. D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O. E., Ferguson, V., Seckl, M. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845345/ https://www.ncbi.nlm.nih.gov/pubmed/36650166 http://dx.doi.org/10.1038/s41467-023-35969-4 |
Ejemplares similares
-
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
por: Coombes, R. C., et al.
Publicado: (2022) -
The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells
por: Na, Yu Ran, et al.
Publicado: (2021) -
Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
por: Kähkönen, T. E., et al.
Publicado: (2020) -
Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study
por: Liang, Donglou, et al.
Publicado: (2017) -
Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer
por: Shan, Liping, et al.
Publicado: (2019)